Noninvasive prenatal testing (NIPT) is also known as a noninvasive prenatal diagnosis (NIPD). Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) or a sex chromosome irregularity, such as Turner syndrome. The testing can also be used to determine a baby’s sex and rhesus (Rh) blood type. The Non-Invasive Prenatal Test (NIPT) is a DNA test on maternal blood to screen for the fetal aneuploidies (chromosomes 21, 18, 13) during pregnancy. Now, noninvasive prenatal testing is only available for women who have certain risk issue. Non-invasive prenatal testing (NIPT) offers harmony, verify, Panorama, informaSeq, VisibiliT, PrenaTest, BambniTest and another test.
Request Sample Report @ http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=50313
The NIPT market is growing, due to rising healthcare expenditure. The common maternal age is rising in high-income countries, owing to varying pattern of employment, education and marriage and growing price of raising a child. The increase in common maternal age is resulting in the development of the global NIPT market. The exponential growth of the NIPT market is supported by factors such as high birth rate with Down syndrome, no risk of miscarriage with NIPT, and the shifting trend toward childbearing at advanced maternal age.
The report includes the detailed competitive landscape of the global Non-Invasive Prenatal Test market and an analysis of Porter’s five forces model for the Non-Invasive Prenatal Test market has also been included. It includes company market share analysis, the product portfolio of the major industry participants. The report provides detailed segmentation of the Non-Invasive Prenatal Test market based on Test and region segment. Bambi test, harmony, informaSeq, materniT21 PLUS, NIFTY, panorama, PrenaTest, verify, VisibiliT is the Test of Non-Invasive Prenatal Test market. MaterniT21 PLUS was the most conventional test in the market and led the total market.
Browse the full report @ http://www.syndicatemarketresearch.com/market-analysis/noninvasive-prenatal-testing-nipt-market.html
Major regional segments analyzed in this study include North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa with its further bifurcation into major countries including U.S., Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for Non-Invasive Prenatal Test based on individual products and applications in all the regions and countries. The market is expected to be driven by the demand from untapped regions such as Europe and Asia Pacific during the forecast period.
The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Sequenom Inc., BGI, LabCorp, LifeCodexx AG, Natera Inc., Quest Diagnostics Incorporated, Illumina Inc., Berry Genomics, Ariosa Diagnostics and Hoffmann-La Roche Ltd.
Noninvasive Prenatal Testing (NIPT) Market: Test Segment Analysis
- Bambi Test
- MaterniT21 PLUS
Noninvasive Prenatal Testing (NIPT) Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East And Africa
Syndicate Market Research provides a range of marketing and business research solutions designed for our client’s specific needs based on our expert resources. The business scopes of Syndicate Market Research cover more than 30 industries including energy, new materials, transportation, daily consumer goods, chemicals, etc. We provide our clients with the one-stop solution for all the research requirements.
3422 SW 15 Street,Suite #8138
Deerfield Beach,Florida 33442
Toll Free: +1-855-465-4651 (USA-CANADA)